International Research Highlight
BRAF and MEK inhibition (BRAF+MEKi) and immune-checkpoint inhibition (ICI) have each drastically improved the outcomes of patients with metastatic melanoma. BRAF+MEKi (for those with BRAFV600-mutant disease) results in higher objective response rates (ORRs), whereas ICI typically results in more-durable responses. Importantly, these treatments have distinct mechanisms of action and thus considerable interest has been placed on combining them. Now, results from three early phase clinical trials in patients with previously untreated metastatic BRAFV600-mutant melanoma highlight the promise of this strategy.
Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten
Passend zum Thema
DKK 2020/© [M] Noppasinw / stock.adobe.com